Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03837184
Recruitment Status : Not yet recruiting
First Posted : February 12, 2019
Last Update Posted : April 10, 2019
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
AveXis, Inc.

Brief Summary:
This is a Phase 3, open-label, single-arm, single-dose, trial of AVXS-101 (gene replacement therapy) in participants with spinal muscular atrophy (SMA) Type 1 and who are genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 gene (SMN1) with one or two copies of survival motor neuron 2 gene (SMN2). The primary objective of the study is to evaluate the efficacy of AVXS-101 by assessing the proportion of symptomatic SMA Type 1 participants who achieve the ability to sit unaided for at least 10 seconds up to and including the 18 months of age trial visit. At least 6 participants aged < 6 months (< 180 days) at the time of gene replacement therapy (Day 1) will be enrolled.

Condition or disease Intervention/treatment Phase
Spinal Muscular Atrophy Type I Biological: AVXS-101 Phase 3

Detailed Description:

This is a Phase 3, open-label, single-arm, single-dose trial of AVXS-101 (gene replacement therapy) in participants with SMA Type 1 with one or 2 copies of SMN2. At least 6 participants < 6 months (< 180 days) of age at the time of gene replacement therapy (Day 1) will be enrolled.

The trial includes 3 trial periods: screening, gene replacement therapy, and follow-up. During the screening period (Days -30 to -2), participants whose parent(s)/legal guardian(s) provide informed consent will undergo screening procedures to determine eligibility for trial enrollment. participants who meet the entry criteria will enter the in-patient gene replacement therapy period (Day -1 to Day 3). On Day -1, participants will be admitted to the hospital for pre-treatment baseline procedures. On Day 1, participants will receive a one-time intravenous (IV) infusion of the equivalent of AVXS-101 cohort 2 dose received in the AVXS-101-CL-101 trial over approximately 60 minutes and will undergo in-patient safety monitoring over the next 48 hours. Participants may be discharged 48 hours after gene replacement therapy, based on Investigator judgment. During the outpatient follow-up period (Days 4 to End of Trial at 18 months of age), participants will return at regularly scheduled intervals for efficacy and safety assessments until the participant reaches 18 months of age.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Estimated Study Start Date : April 30, 2019
Estimated Primary Completion Date : March 23, 2021
Estimated Study Completion Date : March 23, 2021


Arm Intervention/treatment
Experimental: AVXS-101
Participants will receive a single dose of AVXS-101, administered intravenously.
Biological: AVXS-101
AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.




Primary Outcome Measures :
  1. Proportion of Participants Sitting Without Support [ Time Frame: Up to 18 Months of Age Visit (Up To 14 Days After Participant Reaches 18 Months of Age) ]
    The proportion of symptomatic SMA Type 1 participants who are homozygous negative for SMN1 exon 7 and have 2 copies of SMN2 without the SMN2 genetic modifier that achieve the ability to sit without support for at least 10 seconds. 'Sitting without support' is defined by the WHO Multicentre Growth Reference Study as "a patient who sits up straight with head erect for at least 10 seconds; child does not use arms or hands to balance body or support position".


Secondary Outcome Measures :
  1. Proportion of Participants Surviving [ Time Frame: 14 Months of Age Visit (Up To 14 Days After Participant Reaches 18 Months of Age) ]
    The proportion of participants at 14 months of age amongst symptomatic SMA Type 1 participants who are homozygous negative for SMN1 exon 7 and have 2 copies of SMN2 without the SMN2 genetic modifier. 'Survival' is defined as the avoidance of the combined endpoint of either (a) death or (b) permanent ventilation, which is defined by tracheostomy or by the requirement of ≥ 16 hours of respiratory assistance per day (via non-invasive ventilatory support) for ≥ 14 consecutive days in the absence of an acute reversible illness, excluding perioperative ventilation. Permanent ventilation, so defined, is considered a surrogate for death.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 6 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants with SMA Type 1 as determined by diagnosis of SMA based on gene mutation analysis with biallelic SMN1 mutations (deletion or point mutations) and one or 2 copies of SMN2 [inclusive of the known SMN2 gene modifier mutation (c.859G>C)]
  • Participants must be < 6 months (< 180 days) of age at the time of AVXS-101 infusion
  • Participants must have a swallowing evaluation test performed prior to administration of gene replacement therapy
  • Up-to-date on childhood vaccinations. Seasonal vaccinations that include palivizumab prophylaxis (also known as Synagis) to prevent respiratory syncytial virus (RSV) infections are also recommended
  • Parent(s)/legal guardian(s) willing and able to complete the informed consent process and comply with trial procedures and visit schedule

Exclusion Criteria:

  • Previous, planned or expected scoliosis repair surgery/procedure prior to 18 months of age
  • Use of invasive ventilatory support (tracheotomy with positive pressure) or pulse oximetry < 95% saturation at screening:

    1. Pulse oximetry saturation must not decrease ≥ 4 percentage points between screening and dosing with confirmatory oximetry reading
    2. Participants may be put on non-invasive ventilatory support for less than 12 hours perday at the discretion of their physician or trial staff
  • Use or requirement of non-invasive ventilatory support for 12 or more hours daily in the two weeks prior to dosing
  • Participant with signs of aspiration based on a swallowing test or whose weight-for-age falls below the 3rd percentile based on World Health Organization (WHO) Child Growth Standards and unwilling to use an alternative method to oral feeding
  • Active viral infection (includes human immunodeficiency virus [HIV] or positive serology for hepatitis B, C, or E, or known Zika virus infection)
  • Serious non-respiratory tract illness requiring systemic treatment and/or hospitalization within 2 weeks prior to screening
  • Upper or lower respiratory infection requiring medical attention, medical intervention, or increase in supportive care of any manner within 4 weeks prior to screening
  • Severe non-pulmonary/respiratory tract infection (eg, pyelonephritis, or meningitis) within 4 weeks before administration of gene replacement therapy or concomitant illness that, in the opinion of the Principal Investigator, creates unnecessary risks for gene replacement such as:

    1. Major renal or hepatic impairment
    2. Known seizure disorder
    3. Diabetes mellitus
    4. Idiopathic hypocalcuria
    5. Symptomatic cardiomyopathy
  • Known allergy or hypersensitivity to prednisolone or other glucocorticosteroids or their excipients, or human, animal biological raw materials (human transferrin, human insulin, trypsin derived from porcine spleen, bovine derived protein (FBS, bovine milk-derived Benzonase, casamino acid, bovine pancreas), HEK 293 cells, Cosmic Calf Serum, HyQtase) used in manufacturing of AVXS-101 product
  • Concomitant use of any of the following: drugs for treatment of myopathy or neuropathy, agents used to treat diabetes mellitus, or ongoing immunosuppressive therapy, plasmapheresis, immunomodulators such as adalimumab, or immunosuppressive therapy within 3 months prior to gene replacement therapy (eg, corticosteroids, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, IV immunoglobulin, rituximab)
  • Anti-AAV9 antibody titer > 1:50 as determined by Enzyme-linked Immunosorbent Assay (ELISA) binding immunoassay. Should a potential participant demonstrate Anti-AAV9 antibody titer > 1:50, he or she may receive retesting within 30 days of the screening period and will be eligible to participate if the Anti-AAV9 antibody titer upon retesting is ≤ 1:50
  • Clinically significant abnormal laboratory values (gamma-glutamyl transpeptidase [GGT], ALT, and AST > 3 × ULN, bilirubin ≥ 3.0 mg/dL, creatinine ≥ 1.0 mg/dL, hemoglobin [Hgb] < 8 or > 18 g/dL; white blood cell [WBC] > 20,000 per cmm) prior to gene replacement therapy
  • Participation in recent SMA treatment clinical trial (with the exception of observational cohort studies or non-interventional studies) or receipt of an investigational or commercial compound, product or therapy administered with the intent to treat SMA (eg, nusinersen, valproic acid) at any time prior to screening for this trial. Oral beta-agonists must be discontinued at least 30 days prior to dosing. Inhaled albuterol specifically prescribed for the purposes of respiratory (bronchodilator) management is acceptable and not a contraindication at any time prior to screening for this trial
  • Expectation of major surgical procedures during the trial assessment period (eg, spinal surgery or tracheostomy)
  • Parent(s)/legal guardian(s) unable or unwilling to comply with trial procedures or inability to travel for repeat visits
  • Parent(s)/legal guardian(s) unwilling to keep trial results/observations confidential or to refrain from posting confidential trial results/observations on social media sites
  • Parent(s)/legal guardian(s) refuses to sign consent form
  • Participants < 35 weeks gestational age at time of birth

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03837184


Contacts
Layout table for location contacts
Contact: AveXis Medinfo 833-828-3947 medinfo@avexis.com

Locations
Layout table for location information
Japan
Tokyo Women's Medical University Not yet recruiting
Tokyo, Japan
Contact: Tokyo Women's Medical University         
Korea, Republic of
Republic of Pusan National University Children's Hospital Not yet recruiting
Pusan, Korea, Republic of
Taiwan
National Taiwan University Hospital Not yet recruiting
Taipei, Taiwan
Sponsors and Collaborators
AveXis, Inc.
PRA Health Sciences
Investigators
Layout table for investigator information
Study Director: Medical Director AveXis, Inc.

Layout table for additonal information
Responsible Party: AveXis, Inc.
ClinicalTrials.gov Identifier: NCT03837184     History of Changes
Other Study ID Numbers: AVXS-101-CL-306
First Posted: February 12, 2019    Key Record Dates
Last Update Posted: April 10, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by AveXis, Inc.:
Spinal Muscular Atrophy
SMN2
AVXS-101
Gene replacement therapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Atrophy
Muscular Atrophy
Muscular Atrophy, Spinal
Spinal Muscular Atrophies of Childhood
Pathological Conditions, Anatomical
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Spinal Cord Diseases
Central Nervous System Diseases
Motor Neuron Disease
Neurodegenerative Diseases
Neuromuscular Diseases
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn